Single agent high-dose cisplatin (200 mg m-2) treatment in ovarian carcinoma.

Twenty patients with epithelial ovarian carcinoma were treated with high-dose cisplatin 200mg m-2. Patients were to receive three cycles at 21 day intervals. Treatment was stopped if severe myelosuppression or any neurotoxicity occurred. Overall, eight (40%) of patients responded with a complete res...

Descripción completa

Detalles Bibliográficos
Autores principales: Kehoe, S., Redman, C., Varma, R., Buxton, J., Luesley, D., Blackledge, G., Stanley, A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977413/
https://www.ncbi.nlm.nih.gov/pubmed/1419613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977413/
https://www.ncbi.nlm.nih.gov/pubmed/1419613

Ejemplares similares